Potential Drug for Cutaneous Lupus Found Safe and Effective in Phase 2 Trial

Angie Davidson

5 June 2020

Various

Potential Drug for Cutaneous Lupus Found Safe and Effective in Phase 2 Trial

Biogen Inc shared positive data from the 16-week cutaneous lupus erythematosus (CLE) portion of the Phase 2 LILAC study. The study evaluated the efficacy and safety of BIIB059, the data were presented at the European E-Congress of Rheumatology (EULAR) 2020.

Angie Davidson

9 January 2019

USA

Study Shows Rituximab May Be Effective at Treating Cutaneous Lupus Erythematosus

Angie Davidson

9 January 2019

USA

Study Shows Rituximab May Be Effective at Treating Cutaneous Lupus Erythematosus

A new study has found that B-cell depletion therapy (which destroys autoimmune disease producing B cells) using rituximab has the potential to treat skin lesions in people with severe active cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

THE CONTENT ON THIS WEBSITE SHOULD NOT BE SEEN AS SUBSTITUTE FOR MEDICAL ADVICE. IF YOU HAVE, OR THINK YOU MAY HAVE, LUPUS, ALWAYS SEEK ADVICE FROM A QUALIFIED PHYSICIAN. FIND OUT MORE IN OUR TERMS OF USE.